Effectiveness of Clinical Decision Support Tools on Pediatrician Adherence to Peanut Allergy Prevention Guidelines | Allergy and Clinical Immunology | JAMA Pediatrics | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.234.223.227. Please contact the publisher to request reinstatement.
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Research Letter
    October 14, 2019

    Effectiveness of Clinical Decision Support Tools on Pediatrician Adherence to Peanut Allergy Prevention Guidelines

    Author Affiliations
    • 1Feinberg School of Medicine, Northwestern University, Chicago, Illinois
    • 2Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, Illinois
    JAMA Pediatr. 2019;173(12):1198-1199. doi:10.1001/jamapediatrics.2019.3360

    Peanut allergy (PA) affects 2.2% of children in the United States.1 The Learning Early About Peanut Allergy (LEAP) study2 prompted the National Institute for Allergy and Infectious Disease to create the 2017 Addendum Guidelines for the Prevention of Peanut Allergy. The guidelines recommend that clinicians screen infants aged 4 to 6 months for PA risk. Infants at high risk (those with severe eczema and/or egg allergy) should receive a specific IgE (sIgE) or an allergy referral for assessment prior to peanut product introduction, while infants with low or moderate risk (with mild-moderate or no eczema) can have peanut products introduced and maintained in their diet.3 The possible prevention of PA in infants depends on pediatricians incorporating guidelines in well-child visits for infants aged 4 to 6 months. Clinical decision support (CDS) tools are an effective way to facilitate physician adherence to clinical guidelines.4 This study examines the effectiveness of a pediatrician-designed CDS tool and training on pediatrician adherence to the guidelines.

    ×